MUDr. Kateřina BOUCHALOVÁ, Ph.D. (rozená Špačková)

Adresa pracoviště:

Laboratoř experimentální medicíny při Dětské klinice LF UP a FN Olomouc, Puškinova 6, 775 20 Olomouc,

Telefon :  +420 588 444 460, Fax : +420 588 442 527, 

e-mail:

 

Vzdělání:

1988-1994        Lékařská fakulta , Universita Palackého, Olomouc, všeob. lékařství

1993                Výměnná stáž Univerzitní nemocnice, Leiden, Nizozemí

1994                Výměnná stáž Univerzitní nemocnice, Homburg, Německo

1997                Atestace z pediatrie I.stupně

2000-05            Postgraduální doktorské studium  - Prognostický význam cytogenetických změn u solidních nádorů  ve vztahu

                       k odpovědi na terapii, Laboratoř experimentální medicíny, Dětská klinika, LF UP Olomouc,

2006                Specializovaná způsobilost pediatrie

 

Akademická činnost:

2001-               Semináře pro anglický studijní program, Dětská klinika LF UP Olomouc,

2004-               Odborná asistentka, Dětská klinika, LF UP Olomouc,

2006-               Školitelka, Studentská vědecká odborná činnost, Dětská klinika, LF UP Olomouc.          
2008-               Školitelka, Doktorský studijní program, Dětská klinika, LF UP Olomouc.

 

Nemocniční činnost:

1994-2000        Nemocnice Šumperk, s.r.o.,

2001-               Dětská klinika FN Olomouc,

2003-               Laboratoř experimentální medicíny, Dětská klinika, LF UP Olomouc,

2004-               Dětská klinika LF UP Olomouc

 

Hlavní oblasti vědeckého zájmu: cytogenetické změny u solidních nádorů, hormonálně aktivní nádory, prediktivní onkologie

 

Členství ve společnostech: Česká lékařská společnost J.E.Purkyně, Česká hematologická společnost ČLS JEP, Biologická společnost, Onkologická společnost ČLS JEP, sekce prediktivní onkologie, European Cytogeneticists Association (E.C.A)

 

BIBLIOGRAFIE:

 

A. Původní a přehledové práce:

1. Mihál V., Gregůrková J., Michálková K., Pospíšilová D., Novák Z., Špačková K., Stejskalová I., Petříková A., Nohýnková E.: An unusual cause of fever, splenomegaly  and leucopenia (clinico-radiology diagnosis). Pediatrie pro praxi 2001(2):2: 83-84.

2. Špačková K., Trojanec R., Šoukalová J., Cwiertka K., Hajdúch M.: Herceptin – the first genetically targeted therapy of breast carcinoma. Klinická farmakologie a farmacie 2002;16(1-2):29-30.

3. Trojanec R., Špačková K., Cwiertka K., Džubák P., Janošťáková A., Kolář Z., Houserková D., Mihál V., Hajdúch M.: Amplification of the Her-2/neu gene: molecular, cellular and clinical aspects. Klinická farmakologie a farmacie 2002;16(1-2):23-29.

4. Kolář Z., Dvořáčková J., Plevová P., Študent V., Hajdúch M., Trojanec R., Špačková K.: What is the Real Significance of the c-erbB-2 (HER-2/neu) Expression in Breast and Prostate Cancer? Československá patologie 2002;38(Supplementum):S15-S19.

5. Cwiertka K., Trojanec R., Špačková K., Hajdúch M.: Therapeutic monoclonal antibodies in oncology. Klinická farmakologie a farmacie 2004;18(3):165-170.

6. Hajdúch M., Jarošová M., Trojanec R., Indrák K., Špačková K., Papajík T., Cwiertka K.: Cytogenetics and molecular biological markers in oncology and hematooncology. Klinická onkologie 2004;17(Supplementum):51-56.   

7. Bouchalova K., Trojanec R., Kolar Z., Cwiertka K., Cernakova I., Mihal V., Hajduch M.: Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006, ;53(5):393-401. ISSN: 0028-2685 IF(2006): 1.247..

8. Cernakova I., Kvasnicova M., Lovasova Z., Badova N., Drabek J., Bouchalova K., Trojanec R., Hajduch M.: A duplication dup(4)(q28q35.2) de novo in a newborn. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006 Jul;150(1):113-6. ISSN 1213-8118.

9. Dziechciarkova M., Berkovcova J, Trojanec R., Srovnal P., Bouchalova K., Hajduch M.: The utilization of laser capture microdissection for construction of specific samples from cancer tissue, in order to microgenomic analyses. Klinická onkologie 2006;19(Supplementum):355-60. ISSN 0862-495X.

10. Turashvili G., Bouchalova K., Bouchal J., Kolar Z.: Expression of E-cadherin and c-erbB-2/HER-2/neu Oncoprotein in High-Grade Breast Cancer. Československá patologie 2007;43:87-92.

11. Dziechciarkova M., Berkovcova J, Trojanec R., Srovnal P., Bouchalova K., Hajduch M.: Application of laser capture microdissection in preparation of complex malignant tissue samples for microgenomic analyses. Klinická onkologie 2007;20:323-9. ISSN 0862-495X (print). ISSN 1802-5307 (online).

 

B. Přednášková a posterová sdělení:

1. Cernakova I., Kvasnicova M., Lovasova Z., Badova N., Seemanova E., Spackova K.: Duplication (4)(q31.1qter) in a newborn with suspicious clinical diagnosis of Nijmegen breakage syndrome, International Congress of Human Genetics, May 15-19, 2001, Wien, Austria, abstract P0267 published in European Journal of Human Genetics 2001;9(Suppl1):152.

2. Špačková K., Gregůrková J., Mihál V., Pospíšilová D., Novák Z., Stejskalová I., Petříková A., Michálková K., Nohýnková E.: An infrequent cause of progressive splenomegaly (case report), XIX. Days of Clinical  and Practical Pediatrics - Congress with International Participation), May 25-26, 2001, Olomouc, Czech Republic.

3. Špačková K., Černáková I., Škarda I., Kolář Z., Hajdúch M.: Examination of the status of the HER-2/neu and TOPOII genes by FISH on paraffin- embedded tissue from patients with breast carcinoma, XXV. Oncology Days, May 30-June 1, 2001, Brno, Czech Republic.

4. Hajdúch M., Nosková V., Cwiertka K., Špačková K., Kořínková G., Gojová L., Trojanec R., Ludková A., Kuzmina G., Thomson J., Džubák P., Kašpárek I., Bražinová S., Firoze W., Černáková I., Mihál V.: Some contemporary possibilities for prediction of the outcome of anticancer therapy, XXV. Oncology Days, May 30-June 1, 2001, Brno, Czech Republic.

5. Špačková K., Gregůrková J., Pospíšilová D., Mihál V., Michálková K., Novák Z., Stejskalová I., Petříková A., Nohýnková E.: An unusual cause of hepatosplenomegaly – case report (poster), XV. Olomouc Hematology Days with International Participation, June 7-9, 2001, Olomouc, Czech Republic.

6. Špačková K., Černáková I., Trojanec R., Hajdúch M., Houserková D., Kolář Z.: The use of FISH in oncogenetics of breast cancer –our experience with the investigation of the status of the Her-2/neu and Topo II α genes on archival, deparafinized and fresh biopsy tissues ,VI. Oncology Day, Prague, June 13, 2001, Czech Republic.

7. Mihál V., Pospíšilová D., Jarošová M., Pikalová Z., Novák Z., Stejskalová I., Špačková K., Nosková V., Hajdúch M.: Biological analysis of prognostic factors of children acute lymphoblastic leukaemia, XI. Working Conference of Czech and Slovak Hematooncologists, June 22-24, 2001, Špičák, Czech Republic.

8. Špačková K., Gregůrková J., Pospíšilová D., Mihál V., Michálková K., Novák Z., Stejskalová I., Petříková A., Nohýnková E.: An unusual cause of progressive hepatosplenomegaly, XI. Working Conference of Czech and Slovak Hematooncologists, June 22-24, 2001, Špičák, Czech Republic.

9. Špačková K., Černáková I., Škarda J., Kolář Z., Hajdúch M.:  Examination of HER-2/neu and TOPOIIa gene status by FISH on formaline fixed paraffin - embedded tissues in breast carcinoma patients, XVI. Biology Days, September 5-7, 2001, Olomouc, Czech Republic.

10. Špačková K., Černáková I.,Trojanec R., Hajdúch M., Houserková D., Kolář Z.: Our experience with the investigation of the status of the Her-2/neu and TOPO II genes using FISH assay on archival, deparafinized and biopsy tissues from breast carcinoma patients, XXXIV. Annual Cytogenetic Conference with International Participation, September 20-21, 2001, Prague, Czech Republic.

11. Černáková I., Špačková K., Trojanec R., Houserková D., Kolář Z., Hajdúch M.: Examination of the status of the HER-2/neu oncogene in patients with breast carcinoma using biopsy tissue imprinting method and deparafinization of archival samples - the comparison of methods, XXXIV. Annual Cytogenetic  Conference with International Participation, September 20-21, 2001, Prague, Czech Republic.

12. Trojanec R., Hajdúch M., Kašpárek I., Špačková K., Černáková I., Šoukalová J.: FISH carried out on different cell lines, XII. Izakovič´s Memorial (Conference with International Participation), October 3-5, 2001, Nové Zámky, Slovak  Republic.

13. Špačková K., Černáková I., Trojanec R., Škarda J., Kolář Z., Houserková D., Hajdúch M.: The use of FISH in oncogenetics of breast cancer –our experience with the investigation of the status of the Her-2/neu and Topo II α genes on archival, deparaffinized and fresh biopsy tissue, XII Izakovič´s Memorial (Conference with International Participation), October 3-5, 2001, Nové Zámky, Slovak Republic.

14. Hajdúch M., Nosková V., Cwiertka K., Špačková K., Kořínková G., Gojová L., Trojanec R., Ludková A., Kuzmina G., Thomson J., Džubák P., Kašpárek I., Bražinová S., Firoze W., Černáková I., Mihál V.: Some contemporary possibilities for prediction of the outcome of anticancer therapy. Doctors´ working meeting, October 6-7, 2001, Valtice, Czech Republic.

15. Špačková K., Trojanec R., Šoukalová J., Kolář Z., Cwiertka K., Houserková D., Hajdúch M.: The evaluation of Her-2/neu and TopoIIa gene by the FISH method and its clinical application in the selecting appropriate adjuvant and neoadjuvant chemotherapy for patients with breast cancer, VIIth symposium of oncology: Gynaecology and mammology, January 18-19, 2002 Congress Centre, Brno, Czech Republic.

16. Hajdúch M., Trojanec R., Špačková K., Šoukalová J.: FISH method for the assessment of the HER-2/neu gene in breast carcinoma. Meeting of health insurance companies representatives and oncology experts, Masaryk´s Oncology Institute, April 12, 2002, Brno, Czech Republic.

17. Trojanec R., Šoukalová J., Špačková K., Hajdúch M.: Status of the Her-2/neu, TOP2A a RARA genes, analysed by FISH method on the  paraffin embedded breast cancer samples. XXVI. Oncology Days, May 29-31, 2002, Brno, Czech Republic.

18. Němcová D., Petříková A., Špačková K., Pospíšilová D., Nohýnková E., Vepřeková L., Doležalová P., Mihál V.: Visceral leishmaniasis mimicking a systemic onset of juvenile idiopathic arthritis (JIA): report of two cases. Annual European Congress of Rheumatology EULAR, June 12-15, 2002, Stockholm, Sweden, abstract published in Annals of the Rheumatic Diseases 2002( July):61(Suppl.I):439.

19. Trojanec R., Šoukalová J., Špačková K., Cwiertka K., Hajdúch M., Kolář Z.:  Status of the Her-2/neu, TOP2A a RARA genes, analysed by FISH method on the  paraffin embedded breast cancer samples. XXXVth Annual Cytogenetic  Conference with International Participation, September 26-27, 2002, Brno, Czech Republic.

20. Trojanec R., Špačková K., Šoukalová J., Sedláková E., Hajdúch M., Kolář Z.: Our experience with the examination of the HER-2/neu, TOP2A and RARA genes in breast carcinoma tissue. Interregional pathology workshop organized by Czech section of International Academy of Pathology, September 26-27, 2002, Opava, Czech Republic. 

21. Kolar K., Murray P.G., Hajduch M., Spackova K.: Does expression of topoisomerase 2a predict the cancer treatment success or failure?, XXIVth International Congress of the International Academy of Pathology, October 5-10, 2002, Amsterdam, The Netherlands, abstract in Histopathology 2002,41 (Suppl.1),76.

22. Hajdúch M., Kolář Z., Trojanec R., Špačková K., Sedláková E., Šoukalová J.: Preliminary results of the HER-2/neu gene status assessment in reference laboratory. Working meeting organized by heatlh insurance companies and Masaryk´s Oncology Institute on the topic: Herceptin – laboratory assessment of the HER-2 receptors and treatment with Herceptin, October 30, 2002, Brno, Czech Republic.

23. Špačková K., Trojanec R., Šoukalová J., Sedláková E., Cwiertka K., Kolář Z., Hajdúch M.: The importance of the HER-2/neu, TOP2A and RARA genes for the therapy of breast carcinoma, our experience with their assessment and new possibilities for genetically targeted therapy. VIIIth symposium Oncology in gynaecology and mammology, January 17-18, 2003 Congress Centre, Brno, Czech Republic.

24. Trojanec R., Spackova K., Soukalová J., Janostakova A., Noskova V., Mihal V., Hajduch M.: In vitro chemosensitivity and genetic status of selected oncogenes in tumour cell lines. 5th International Symposium on Leukemia and Lymphoma, March 12-15, 2003, Amsterdam, The Netherlands. Abstract in Leukemia 2003; 17(3): 680. 

25. Hajdúch M., Kolář Z., Trojanec R., Špačková K., Sedláková E., Šoukalová J.: Results of the HER-2/neu assessment in reference laboratory – state after 8 month. Working meeting of oncologists and health insurance representatives, March 17, 2003, Masaryk´s Oncology Institute, Brno, Czech Republic.

26. Špačková K., Mikušková E., Konrádová H., Poláčková Z., Mihál V.: Tonzilitis with exanthema and splenomegaly – case report, Seminary of Department of Paediatrics, Palacký Univerzity and Faculty Hospital Olomouc, March 19, 2003, Olomouc, Czech Republic.

27. Špačková K., Trojanec R., Kolář Z., Sedláková E., Šoukalová J., Hajdúch M.: Utility of standardization of predictive oncology methods – gene Her-2/neu as a sample. VIIIth Professor Vladimir Stašek´s Days, March 21-22, 2003, Prague, Czech Republic.

28. Hajduch M., Trojanec R., Nosková V., Škarda J., Kolář Z., Špačková K., Sedláková E., Šoukalová J., Mihál V.: Prediction of patient´s treatment response in clinical practice: review of cytogenetic and cell markers. VIIIth Professor Vladimir Stašek´s Days, March 21-22, 2003, Prague, Czech Republic.

29. Nosková V., Gojová L., Trojanec R., Škarda J., Kolář Z., Špačková K., Sedláková E., Šoukalová J., Mihál V., Hajdúch M.: Prediction significance of MDR in non-small cell lung carcinoma. VIIIth Professor Vladimir Stašek´s Days, March 21-22, 2003, Prague, Czech Republic.

30. Hajdúch M., Trojanec R., Nosková V., Džubák P., Kolář Z., Špačková K., Škarda J., Dušek L., Bouchal J., Vydra D., Cwiertka K., Žaloudík J., Mihál V.: Methods of prognostic/predictive onkology: From where we came, where we are coming. Analytic Flow-cytometry Conference II, May 11th-14th 2003, Brno, Czech Republic.

31. Trojanec R., Špačková K., Kolář Z., Sedláková E., Mihál V., Hajdúch M.:  The  Her-2/neu gene, standardization of FISH assay and possibilities of interlaboratory verification. Analytic Flow-cytometry Conference II, May 11th-14th 2003, Brno, Czech Republic.

32. Trojanec R., Špačková K., Kolář Z., Sedláková E., Šoukalová J., Mihál V., Hajdúch M.: The  Her-2/neu (c-erbB-2) gene – results and experiences of reference laboratory. XXVII. Brno´s Oncology Days, May 22nd-24th 2003, Brno, Czech Republic.

33. Trojanec R., Špačková K., Šoukalová J., Mihál V., Hajdúch M.: Status of the Her-2/neu, TOP2A, Cyclin D1, c-myc, p53, and RB1genes in correlation with chemotherapy response in  cancer cells. XXVII. Brno´s Oncology Days, May 22nd-24th 2003, Brno, Czech Republic.

34. Hajdúch M., Trojanec R., Nosková V., Džubák P., Kolář Z., Špačková K., Škarda J., Dušek L., Bouchal J., Vydra D., Cwiertka K., Žaloudík J., Mihál V.: Rational  individualization of anti-cancer treatment – molecular, cellullar and clinical aspects. XXVII. Brno´s Oncology Days, May 22nd-24th 2003, Brno, Czech Republic.

35. Špačková K., Trojanec R., Šoukalová J., Mihál V., Cwiertka K., Hajdúch M.: Retinoic acid receptor alpha – predictive factor in solid tumors. XXVII. Brno´s Oncology Days, May 22nd-24th 2003, Brno, Czech Republic.

36. Cwiertka K., Kapustová M., Vočková J., Kolář Z., Špačková K., Schneiderka P., Macháček J., Hajdúch M., Assessment of extracellular c-erbB2 (Her-2/neu) domain in patients with breast carcinoma – possibility of Herceptin treatment monitoring?, XXVII. Brno´s Oncology Days, May 22nd-24th 2003, Brno, Czech Republic.

37. Palácová M., Petráková K., Hajdúch M., Jandáková E., Trojanec R., Gálová M., Obermannová R., Macková D., Špačková K.: Using the HER-2/neu and the Topoisomerase II alpha in prediction of anthracycline response in locally advanced breast carcinoma. XXVII. Brno´s Oncology Days, May 22nd-24th 2003, Brno, Czech Republic.

38. Špačková K., Trojanec R., Kolář Z., Cwiertka K., Hajdúch M.: Herceptin – the chance for patients, the risk for health insurance companies?. Working day of auditor doctors, May 23th 2003, Praha, Czech Republic.

39. Trojanec R., Špačková K., Kolář Z., Hajdúch M.: Predictive importance of RARA and TOP2A genes laboratory assessment. Pathology Conference, June 21th-22 nd 2003, Srní, Czech Republic.

40. Hajdúch M., Kolář Z., Trojanec R., Sedláková E., Špačková K.: Previous results and experience of Reference laboratory for the Her-2/neu assessment. Pathology Conference, June 21th-22 nd 2003, Srní, Czech Republic.

41. Špačková K., Trojanec R., Kolář Z., Sedláková E., Cwiertka K., Mihál V., Hajdúch M.: Assessment of the RARA (retinoic acid receptor alpha) gene in breast carcinoma - utilization for tailoring therapy? XIV Izakovič´s Memorial (Conference with International Participation), October 23rd-24th, 2003, Trenčianské Teplice, Slovak Republic.

42. Trojanec R., Špačková K., Kolář Z., Sedláková E., Mlčochová S., Mihál V., Hajdúch M.: Assessment of the HER-2/neu gene for the routine practice. XIV Izakovič´s Memorial (Conference with International Participation), October 23rd-24th, 2003, Trenčianské Teplice, Slovak Republic.

43. Hajdúch M., Petráková K., Kolář Z., Trojanec R., Špačková K., Palácová M., Sedláková E.: Current information about c-erb-2 gene assessment in the Reference Laboratory and proposal of changes in indication criteria. Working meeting organized by heatlh insurance companies and Masaryk´s Oncology Institute, April 23, 2004, Brno, Czech Republic.

44. Špačková K.: HER-2/neu and TOP2A genes assessment by FISH in breast carcinoma.   Seminary for PhD students of Medical Faculty, Palacký Univerzity, May 22, 2004, Olomouc, Czech Republic.

45. Hajduch M., Palacova M., Trojanec R., Dusek L., Petrakova K., Spackova K., Obermannova R., Galova M., Blazkova S., Vyzula R.: Anthracycline based chemotherapy decreases amplification status of Her-2/neu and topoisomerase II alpha genes in locally advanced breast cancer (poster). ASCO, 40th Annual Meeting, June 5-8, 2004, New Orleans, LA. Abstract 9521 in Annual Meeting Proceedings 2004;23:836.

46. Hajdúch M., Trojanec R., Špačková K., Kolář Z.: Detection of chromosome 17 polysomy in breast carcinoma and correlation to HER-2/neu gene amplification. XXXVIIth Annual Cytogenetic Conference with International Participation, September 9-10, 2004, Olomouc, Czech Republic.

47. Trojanec R., Hajdúch M, Kolář Z., Spackova K., Braunerová B., Sedláková E., Mlčochová S.: Two-years experience of the Her-2/neu (c-erbB-2) gene status evaluation in the National reference centre for the Czech Republic. 9th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumours, September 16-19, 2004, Brno, Czech Republic.

48. Hajduch M., Palacova M., Trojanec R., Dusek L., Petrakova K., Spackova K., Obermannova R., Galova M., Blazkova S., Vyzula R.: Decrease in amplification status of HER-2/neu and topoisomerase II alpha genes in patients undergoing anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer. 9th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumours, September 16-19, 2004, Brno, Czech Republic.

49. Spackova K., Trojanec R., Kolar Z., Sedlakova E., Cwiertka K., Mihal V., Hajduch M.: RARA gene assessment by FISH in breast carcinoma tissues.  7th International Conference of Anticancer Research, October 25-30, 2004, Dassia, Corfu, Greece. Abstract published in Anticancer Research 2004;24(5D):3640-3641, ISSN: 0250-7005.

50. Trojanec R., Hajduch M., Spackova K., Kolar Z., Sedlakova E., Mlcochova S.: Her-2/neu (c-erbB-2) gene status evaluation in the Czech National Reference Centre. 7th International Conference of Anticancer Research, October 25-30, 2004, Dassia, Corfu, Greece. Abstract published in Anticancer Research, 2004;24(5D):3658. ISSN: 0250-7005.

51. Hajduch M., Trojanec R., Spackova K., Kolar Z., Sedlakova E., Mlcochova S.: Amplification of centromeric signal chromosome 17 polysomy and Her-2/neu gene amplification status in metastatic breast cancer patients”7th International Conference of Anticancer Research, October 25-30, 2004, Dassia, Corfu, Greece. Abstract published in Anticancer Research, 2004;24(5D):3658-3659. ISSN: 0250-7005.

52. Hajdúch M., Kolář Z., Trojanec R., Bouchalová K., Sedláková E: Current information about c-erb-2 gene assessment in the Reference Laboratory. Working meeting organized by heatlh insurance companies and Masaryk´s Oncology Institute, December 13, 2004, Brno, Czech Republic.

53. Trojanec R., Hajduch M., Bouchalova K., Kolar Z., Braunerova B., Sedlakova E.: Limits of FISH method in chromosome 17 copy assessment in breast carcinoma using direct labeled alfa satellite (centromeric) probes. Xth Professor Vladimir Stašek´s Days, March 4-5, 2005, Top hotel, Prague, Czech Republic. 

54. Trojanec R., Hajduch M., Bouchalova K., Braunerova B., Kolar Z., Sedlakova E.: True and untrue amplification of HER-2/neu in breast cancer. Molecular pathology of the beginning of the IIIrd millennium: the use of bioptic samples for molecular analysis (workshop), April 1-2, Olomouc, Czech Republic.

55. Hajduch M., Trojanec R., Bouchalova K., Kolar Z., Petrakova K, Cwiertka K., Svoboda M.: Chromosome 17 polysomy and Her-2/neu status in metastatic breast cancer patients indicated to trastuzumab therapy. ASCO, 41th Annual Meeting, May 13-17, 2005, Orlando, Florida, poster, abstract 9584 published in 2005 Annual Meeting Proceedings, Journal of Clinical Oncology 2005;23(16S):857.

56. Hajdúch M., Trojanec R., Kolář Z., Bouchalová K., Sedláková E: Information about c-erb-2 gene assessment in the Reference Laboratory. Working meeting organized by heatlh insurance companies and Masaryk´s Oncology Institute, May 20, 2005, Brno, Czech Republic.

57. Trojanec R., Hajdúch M., Bouchalová K., Palácová M., Vyzula R., Petráková K., Braunerová B., Kolář Z., Sedláková E., Mlčochová S. Her-2/neu (c-erbB-2) gene status and our experience with its 3-year assessment in Reference laboratory. XXIX. Brno´s Oncology Days, May 25th-28th, 2005, Brno, Czech Republic.

58. Hajdúch M., Trojanec R., Bouchalová K.,  Braunerová B., Cwiertka K.: Chromosome 17 pathology in solid tumors. XXIX. Brno´s Oncology Days, May 25th-28th, 2005, Brno, Czech Republic.

59. Trojanec R., Hajdúch M., Braunerová B., Bouchalová K., Mlčochová S.: Problems of accreditation process and importance of accreditation for the quality of assessment in cytogenetic laboratory. Analytic cytometry III - conference with international participation, June 21th-25th, 2005, Červenohorské sedlo, Czech Republic.

60. Trojanec R., Hajdúch M., Bouchalová K., Cwiertka K., Kolář Z., Sedláková E., Mlčochová S.: Possibilities in prediction of treatment response. Regional seminary of Oncology Clinic, Faculty Hospital Olomouc, and Laboratory of Experimental Medicine, October 10th, 2005, Přerov, Czech Republic.

61. Bouchalová K.: Prognostic importance of cytogenetic changes in solid tumors in relation to the treatment response. PhD defense, October 26th, 2005, Olomouc, Czech Republic.

62. Hajdúch M., Trojanec R., Kolář Z., Bouchalová K., Sedláková E.: Current results from  the Reference Laboratory. Working meeting organized by heatlh insurance companies and oncologists, November 11th, 2005, Brno, Czech Republic.

63. Trojanec R., Hajdúch M., Palácová M., Vyzula R., Petráková K., Braunerová K., Bouchalová K., Kolář Z., Sedláková E., Mlčochová S.: Her-2/neu (c-erbB-2) gene status and our experience with its assessment in the Reference Laboratory. Days of diagnostic, predictive and experimental oncology, December 9th-10th, 2005, Olomouc, Czech Republic.

64. Braunerová B., Trojanec R., Hajdúch M., Bouchalová K., Mlčochová S., Micková M.: Problems and possibilities of accreditation process and the importance of accreditation for the laboratory. Days of diagnostic, predictive and experimental oncology, December 9th-10th, 2005, Olomouc, Czech Republic.

65. Hajdúch M., Trojanec R., Kolář Z., Bouchalová K., Sedláková E.: Current results from  the Reference Laboratory. Working meeting organized by heatlh insurance companies and oncologists, May 26th, 2006, Brno, Czech Republic.

66. Trojanec R., Bouchalová K., Palková V., Braunerová B., Kolář Z., Krejčí V., Hajdúch M.: Limitation of chromosome 17 copy number assesment by FISH using alpha satelite (centromeric) probes in breast cancer patients. Seminář Sepetná 2006: Modulace signálních a regulačních drah normální a nádorové buňky, May 18th-20th, 2006, Ostravice, Czech Republic.

67. Hajdúch M., Trojanec R., Kolář Z., Bouchalová K., Sedláková E.: Current results from  the Reference Laboratory. Working meeting organized by heatlh insurance companies and oncologists, May 26th, 2006, Brno, Czech Republic.

68. Mihál V., Bouchalová K., Pospíšilová D., Novák Z., Hajdúch M., Jarošová M.:  Rizikové faktory pro vznik dětských nádorových onemocnění. IX. Olomoucké dny zdraví, November 23th-24th, 2006, Regionální centrum Olomouc, Czech Republic.

69. Cwiertka K., Krejčí E., Beneš P., Kapustová M., Bouchalová K., Kolář Z., Hajdúch M.: Co rozhoduje o nasazení trastuzumabu? Days of diagnostic, predictive and experimental oncology, December 7th-9th, 2006, Olomouc, Czech Republic.

70. Dziechciarkova M., Berkovcova J, Trojanec R., Srovnal P., Bouchalova K., Hajduch M.: Application of laser capture microdissection in preparation of complex malignant tissue samples for microgenomic analyses. XXXI. Brno´s Oncology Days, April 23rd-25th, 2007, Brno, Czech Republic.

71. Dziechciarkova M., Trojanec R., Kolar Z., Bouchalova K., Braunerova B., Hajduch M.: Enhanced possibilities of HER2/neu detection using wider spectrum of cytogenetic probes and monoclonal antibodies. Days of diagnostic, predictive and experimental oncology, November 28th-30th, 2007, Olomouc, Czech Republic.

 

C. Granty:

1. 2001-2002 řešitelka grantu LF UP „Vyšetření statusu genů HER-2/neu a TOPOII metodou FISH na parafinových řezech u pacientek s karcinomem prsu“. Grantová zpráva přednesena 14.2.2002, hodnocení A.

2. 2001-2002 spoluřešitelka grantu LF UP „Stanovení cytogenetických faktorů v predikci odpovědi nádorových buněk na chemoterapii“. Grantová zpráva přednesena 14.2.2002, hodnocení A.

3. 2003-2005 odborný spolupracovník řešitele grantu IGA 7506-3 „Korelace statusu genů Her-2/neu a TOP2A s klinickou odpovědí nemocných s pokročilým karcinomem prsu na antracyklinový režim“. Hajdúch M., Kolář Z., Cwiertka K., Špačková K., Trojanec R., Džubák P.

4. 2004-   spoluřešitelka grantu Terryho Foxe „Klinický význam koamplifikace genů Her-2/neu (c-erbB-2), RARA a TOP2A u pacientek s neoadjuvantním antracyklinovým léčebným režimem“. Trojanec R., Hajdúch M., Špačková K., Petráková K., Palácová M.

 

 

oponenti intranet